Compare RCMT & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RCMT | SPRO |
|---|---|---|
| Founded | 1971 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 135.6M | 124.5M |
| IPO Year | 1997 | 2017 |
| Metric | RCMT | SPRO |
|---|---|---|
| Price | $19.73 | $2.29 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $30.00 | N/A |
| AVG Volume (30 Days) | 40.8K | ★ 310.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.34 | N/A |
| Revenue | ★ $186,737,000.00 | $47,977,000.00 |
| Revenue This Year | $16.29 | N/A |
| Revenue Next Year | $6.92 | N/A |
| P/E Ratio | $14.89 | ★ N/A |
| Revenue Growth | ★ 5.83 | N/A |
| 52 Week Low | $13.20 | $0.51 |
| 52 Week High | $28.19 | $3.09 |
| Indicator | RCMT | SPRO |
|---|---|---|
| Relative Strength Index (RSI) | 54.87 | 47.97 |
| Support Level | $19.35 | $2.15 |
| Resistance Level | $21.12 | $2.44 |
| Average True Range (ATR) | 0.69 | 0.09 |
| MACD | 0.21 | 0.00 |
| Stochastic Oscillator | 67.19 | 53.00 |
RCM Technologies Inc is a provider of business and technology solutions designed to enhance and maximize the operational performance of its customers. It operates in three segments: Specialty Health Care, Engineering, and Life Sciences, Data and Solutions (LS&D). The company generates maximum revenue from the Specialty Health Care segment that provides staffing solutions including medical healthcare professionals, health information management professionals, nurses, paraprofessionals, physicians, and therapists. Geographically, it derives a majority of its revenue from the United States and also has a presence in Canada, Puerto Rico, the Philippines, and Europe.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.